Yorvipath

News

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

News

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma.

News

In the midst of appointing his Cabinet, new UK Prime Minister Andy Burnham has scrapped the Department for Science, Innovation and Technology (DSIT).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.